Comparison tool
Pasireotide vs Octreotide side-by-side
Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.
Comparison tool
Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.
Selected (2/4)
Share this peptide comparison
| Property | Pasireotide | Octreotide |
|---|---|---|
| Category | Hormonal | Hormonal |
| Also known as | Signifor, Signifor LAR | Sandostatin, Octreotide LAR, Sandostatin LAR, Mycapssa |
| FDA approved | Yes | Yes |
| Clinical status | FDA approved for Cushing's disease and acromegaly
| FDA Approved - Multiple indications
|
| What to expect | Cushing's disease, acromegaly, hormone disorders | Acromegaly, carcinoid tumors, hormone regulation |
| How it works | Pasireotide is reported to act across four somatostatin receptor subtypes: SSTR1, SSTR2, SSTR3, and SSTR5. The source emphasizes SSTR5 affinity, which is relevant to corticotroph tumors in Cushing's disease and ACTH suppression. For acromegaly, the described receptor targets include SSTR2 and SSTR5 on tumors that secrete growth hormone. The same receptor activity in pancreatic and gastrointestinal tissues is presented as a contributor to reduced insulin, GLP-1, and GIP signaling, which may explain the high rate of hyperglycemia reported in trials. | Octreotide is presented as a synthetic analog of somatostatin. The evidence describes preferential binding at SSTR2 and SSTR5, followed by intracellular signaling changes involving adenylate cyclase and calcium channels. Those receptor effects are associated with lower secretion of growth hormone, glucagon, insulin, gastrin, and other gut hormones. In the supplied acromegaly context, reduced growth hormone output is linked with lower IGF-1; in carcinoid-related symptoms, the source also connects activity to slower gut motility and reduced splanchnic blood flow. |
| Typical dosing | 300-900 mcg twice daily · Twice daily (SC) or monthly (LAR) | 100-500 mcg SC 2-3x daily or LAR monthly · 2-3x daily (SC) or monthly (LAR) · Subcutaneous or intramuscular depot |
| Research dosing | 600-900 mcg SC twice daily · Long-term / chronic use · Subcutaneous or intramuscular | 50-200 mcg SC 3x daily (immediate) · Long-term / chronic use · Subcutaneous or intramuscular depot |
| Typical duration | Long-term / chronic use | Long-term / chronic use |
| Administration | Subcutaneous or intramuscular | Subcutaneous injection, intramuscular depot, or oral capsule formulations are reported. |
| Timing | Morning or as directed With or without food | Morning or as directed With or without food |
| Evidence level | FDA Approved | FDA Approved |
| Possible side effects |
+4 more
|
+5 more
|
| Research summary | The source describes randomized clinical evidence in Cushing's disease and acromegaly. In the 12-month Cushing's disease phase 3 study, 162 participants were randomized and urinary free cortisol normalization was reported in about 15% to 26% depending on dose, along with broader cortisol reductions and symptom measures. In acromegaly, the PAOLA phase 3 trial is described as showing biochemical control in roughly 15% to 20% of patients receiving pasireotide LAR after inadequate response to octreotide or lanreotide, compared with 0% in those continuing older analog therapy. Across these trial summaries, hyperglycemia is a repeated safety concern, with glucose-lowering medication sometimes needed. | The supplied evidence characterizes Octreotide as a well-studied peptide drug with human clinical use rather than only laboratory-stage data. It describes long-acting depot use in acromegaly and cites the CHIASMA OPTIMAL phase 3 trial, where oral octreotide maintained biochemical control in about 58% of previously injection-responsive acromegaly patients compared with 19% on placebo over 9 months. The source also reports use in neuroendocrine tumors and carcinoid syndrome, with safety considerations including gallstones, gastrointestinal effects, and altered blood sugar. |
| References | ||
| Full profile | View Details | View Details |
Save this comparison
Keep this research set handy with a free PeptiGuide account.
Save this comparison - free accountTrack your peptide journey
Turn research into a private protocol log when you are ready.
Track your peptide journeyEducational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.